ACHV
Achieve Life Sciences Inc.
$5.14
+$0.02(+0.39%)
54
Overall
60
Value
75
Tech
28
Quality
Market Cap
$144.12M
Volume
787.60K
52W Range
$1.84 - $5.78
Target Price
$16.33
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $18.2M | $5.1M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Total Revenue | $18.2M | $5.1M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-36.9M | $-1.7M | $-6.6M | $-12.8M | $16.5M | $14.8M | $-33.1M | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $18.2M | $1.7M | $6.6M | $12.8M | $-16.5M | $-14.8M | $33.1M | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $36.9M | $1.7M | $6.6M | $12.8M | $16.5M | $14.8M | $33.1M | $40.8M | $27.3M | $39.1M | ||
| Research & Development | $25.1M | $286.0K | $3.1M | $5.9M | $9.7M | $6.9M | $24.0M | $30.1M | $15.8M | $22.8M | ||
| Research Expense | $25.1M | $286.0K | $3.1M | $5.9M | $9.7M | $6.9M | $24.0M | $30.1M | $15.8M | $22.8M | ||
| Selling, General & Administrative | $11.8M | $1.4M | $3.5M | $6.9M | $6.9M | $7.9M | $9.1M | $10.7M | $11.4M | $16.3M | ||
| General & Administrative Expenses | $11.8M | $1.4M | $3.5M | $6.9M | $6.9M | $7.9M | $9.1M | $10.7M | $11.4M | $16.3M | ||
| Salaries & Wages | $-2.3M | $-1.6M | $-348.0K | $-854.0K | $1.2M | $1.3M | $2.2M | $3.3M | $3.4M | $5.3M | ||
| Amortization | -- | $-200.0K | $-200.0K | $-200.0K | $200.0K | $200.0K | $200.0K | $200.0K | $200.0K | $223.0K | ||
| Other Operating Expenses | $-16.0K | $-16.0K | -- | $-6.0K | $-7.0K | $200.0K | $100.0K | $100.0K | $100.0K | $100.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-18.8M | $-1.7M | $-6.6M | $-12.8M | $-16.5M | $-14.8M | $-33.1M | $-40.8M | $-27.3M | $-39.1M | ||
| EBITDA | $-16.6M | $-1.5M | $-13.4M | $-12.4M | $-16.1M | $-14.5M | $-32.9M | $-40.3M | $-29.8M | $-39.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | $1.8M | $2.9M | -- | ||
| Intinc | $119.0K | $-24.0K | $221.0K | $171.0K | $170.0K | $69.0K | $17.0K | $199.0K | $825.0K | $2.4M | ||
| Net Non-Operating Interest Income/Expense | $119.0K | $-24.0K | $221.0K | $171.0K | $170.0K | $69.0K | $17.0K | $-1.6M | $825.0K | $2.4M | ||
| Other Income/Expense | $-1.8M | $24.0K | $7.2M | $45.0K | $37.0K | $49.0K | $75.0K | $40.0K | $537.0K | $934.0K | ||
| Other Special Charges | $1.8M | $-24.0K | $115.0K | $-45.0K | $-37.0K | $-49.0K | $-75.0K | $40.0K | $-9.0K | $-313.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | $-1.1M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | -- | $-1.6M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | $202.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-16.8M | $-1.7M | $-13.6M | $-12.7M | $-16.4M | $-14.7M | $-33.2M | $-40.6M | $-30.0M | $-39.9M | ||
| Pre-Tax Income | $-16.8M | $-1.7M | $-13.6M | $-12.7M | $-16.4M | $-14.7M | $-33.2M | $-42.4M | $-27.0M | $-39.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-13.0K | $-504.0K | $-3.2M | $1.4M | $-104.0K | $-594.0K | $17.0K | $-18.0K | $-169.0K | $-112.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-16.8M | $-1.2M | $-10.6M | $-12.7M | $-16.4M | $-14.7M | $-33.2M | $-42.4M | $-29.8M | $-39.8M | ||
| Net Income (Continuing Operations) | $-16.8M | $-1.2M | $-10.6M | $-12.7M | $-16.4M | $-14.7M | $-33.2M | $-42.4M | $-29.8M | $-39.8M | ||
| Net Income (Discontinued Operations) | $-16.8M | $-1.2M | $-10.6M | $-12.7M | $-16.4M | $-14.7M | $-33.2M | $-42.4M | $-29.8M | $-39.8M | ||
| Net Income (Common Stockholders) | $-16.8M | $-1.2M | $-10.6M | $-12.7M | $-16.4M | $-14.7M | $-33.2M | $-42.4M | $-29.8M | $-39.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-37.1M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-46.4M | $24.7M | -- | -- | $33.1M | $29.5M | $33.1M | $40.8M | $27.3M | $39.1M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $1.3M | $1.5M | $239.7K | $175.5K | $412.3K | $2.7M | $8.1M | $10.6M | $19.8M | $32.1M | ||
| Average Shares Outstanding (Diluted) | $1.3M | $1.5M | $239.4K | $175.7K | $411.9K | $2.7M | $8.1M | $10.6M | $19.8M | $32.1M | ||
| Shares Outstanding | $13.6K | $13.7K | $63.7K | $336.1K | $1.6M | $6.1M | $9.5M | $17.9M | $34.3M | $34.7M | ||
| Basic EPS | -- | -- | -- | -- | -- | -- | -- | $-4 | $-1.5 | $-1.24 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-4 | $-1.5 | $-1.24 | ||
| Diluted EPS | $-12.8 | $-13.4 | $-44.2 | $-72.2 | $-39.8 | $-5.42 | $-4.08 | $-4 | $-1.5 | $-1.24 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-4 | $-1.5 | $-1.24 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | -- | -- | $-8.6M | -- | -- | -- | -- | -- | -- | -- | ||
| Net Income From Other Gains Losses | $18.2M | -- | $3.1M | -- | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | $1.4M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $11.8M | $1.4M | $3.5M | $6.9M | $6.9M | $7.9M | $9.1M | $10.7M | $11.4M | $16.3M | ||
| Rent And Landing Fees | $11.8M | $1.4M | $3.5M | $6.9M | $6.9M | $7.9M | $9.1M | -- | -- | -- | ||
| Restruct | -- | $-1.1M | -- | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ACHV | $5.14 | +0.4% | 787.60K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Achieve Life Sciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW